Castle Biosciences (CSTL)

• Market cap: $639M
• 1 day: -4.66%
• 5 days: 2.73%
• 1 month: -13.04%
• 3 months: -24.69%
• 6 months: -46.11%
• Year to date: -45.3%
• 1 year: 32.16%
• 5 years: -64.74%
• 10 years: -1.5%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Employees: 942